非肝硬化HBeAg阴性慢性乙型肝炎患者停用核苷(酸)类似物:96周时HBsAg清除与低基线HBsAg水平相关
这项前瞻性多中心队列研究纳入110例非肝硬化HBeAg阴性慢性乙型肝炎患者,停用核苷(酸)类似物后随访96周。病毒学再激活非常常见(109/110),停用替诺福韦者较恩替卡韦者更早发生;96周时仅7例(6%)实现HBsAg清除,基线HBsAg≤10 IU/ml与HBsAg清除相关(6/9 vs 1/101,P<0.001)。
要点
- 停用核苷(酸)类似物后病毒学再激活非常常见,中位检测时间为8周。
- 停用替诺福韦者病毒学再激活早于停用恩替卡韦者(中位4 vs 12周,P<0.001)。
- 基线HBsAg≤10 IU/ml与HBsAg清除相关(6/9 vs 1/101,P<0.001)。
核心结论
- 停用核苷(酸)类似物后病毒学再激活非常常见,且停用替诺福韦者较停用恩替卡韦者更早发生。
- 96周时多数患者ALT<2×ULN,但仅约三分之一达到疾病缓解,HBsAg清除罕见。
- 基线HBsAg水平极低者不常见,但可预测HBsAg清除和疾病缓解。
研究设计与样本
- 前瞻性多中心队列研究,纳入110例HBeAg阴性、无肝硬化且HBVDNA低于定量下限≥18个月的慢性乙型肝炎患者,停用核苷(酸)类似物后随访96周。
主要发现
- 110例患者中62%使用恩替卡韦、28%使用替诺福韦、10%使用其他药物;中位年龄56岁,57%为男性,85%为亚洲人,中位基线HBsAg水平为705(214-2325)IU/ml。
- 病毒学再激活发生于109/110例患者,中位检测时间为8(4-12)周,停用替诺福韦者较停用恩替卡韦者更早发生(中位4 vs 12周,P<0.001)。
- 96周时77例(70%)仍未治疗,65例(59%)ALT<2×ULN,31例(28%)达到疾病缓解(HBVDNA<2000 IU/ml且ALT<2×ULN),7例(6%)实现HBsAg清除。
- 基线HBsAg≤10 IU/ml与HBsAg清除相关(6/9 vs 1/101,P<0.001)。
- ALT>5×ULN发生于35例(32%);ALT发作与HBsAg清除无关;无意外安全性问题。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Current guidelines recommend long-term nucleot(s)ide analogue (NA) therapy for patients with HBeAg-negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss. METHODS: We performed a prospective multi-centre cohort study of stopping NA therapy. Inclusion criteria were HBeAg-negative CHB, the absence of cirrhosis and HBVDNA<lower limit of quantification for ≥18 months. We assessed virological and biochemical outcomes including HBsAg loss, as well as NA restart rates, over 96 weeks. RESULTS: In total, 110 patients [62% entecavir (ETV); 28% tenofovir (TDF), 10% other] were enrolled. Median age was 56 years, 57% were male, 85% were Asian, median baseline HBsAg level was 705 (214-2325) IU/ml. Virological reactivation occurred in 109/110 patients, median time to detection was 8 (4-12) weeks, and occurred earlier after stopping TDF versus ETV (median 4 vs. 12 weeks p < 0.001). At week 96, 77 (70%) remained off-treatment, 65 (59%) had ALT <2× ULN, 31 (28%) patients were in disease remission with HBVDNA <2000 IU/ml plus ALT <2× ULN and 7 (6%) patients had lost HBsAg. Baseline HBsAg ≤10 IU/ml was associated with HBsAg loss (6/9 vs. 1/101 p < 0.001). ALT >5× ULN occurred in 35 (32%); ALT flares were not associated with HBsAg loss. There were no unexpected safety issues. CONCLUSION: Virological reactivation was very common after stopping NA therapy and occurred earlier after stopping TDF versus ETV. The majority of patients had ALT <2× ULN at week 96, but only one-third achieved disease remission and HBsAg loss was rare. Very low HBsAg levels at baseline were uncommon but predicted for HBsAg loss and disease remission.
引用
- Hall SAL, Burns GS, Anagnostou D, et al. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels. Aliment Pharmacol Ther. 2022. PMID: 35521992. doi:10.1111/apt.16968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。